Impact of Deucravacitinib Treatment on Cardiovascular Risk-Associated Scores and Biomarkers in Patients With Active Psoriatic Arthritis Results From Phase 3 Studies (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2296; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; No abstract available
Biomarker • Clinical • P3 data • Cardiovascular • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies
|